Li Yan
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Silibinin inhibits PM2.5-induced liver triglyceride accumulation through enhancing the function of mitochondrial Complexes I and II.
Journal: Frontiers in pharmacology
Published: May 19, 2024
Angong Niuhuang Wan ameliorates LPS-induced cerebrovascular edema by inhibiting blood‒brain barrier leakage and promoting the membrane expression of AQP4.
Journal: Frontiers in pharmacology
Published: April 22, 2024
QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway.
Journal: Frontiers in pharmacology
Published: April 12, 2022
Yu-Ping-Feng Formula Ameliorates Alveolar-Capillary Barrier Injury Induced by Exhausted-Exercise via Regulation of Cytoskeleton.
Journal: Frontiers in pharmacology
Published: March 08, 2022
QiShenYiQi Pills Attenuates Ischemia/Reperfusion-Induced Cardiac Microvascular Hyperpermeability Implicating Src/Caveolin-1 and RhoA/ROCK/MLC Signaling.
Journal: Frontiers in physiology
Published: August 05, 2021
Yiqifumai injection and its main ingredients attenuate lipopolysaccharide-induced cerebrovascular hyperpermeability through a multi-pathway mode.
Journal: Microcirculation (New York, N.Y. : 1994)
Published: February 24, 2019
QiShenYiQi Pills, a Compound Chinese Medicine, Prevented Cisplatin Induced Acute Kidney Injury via Regulating Mitochondrial Function.
Journal: Frontiers in physiology
Published: October 13, 2017
Catalpol restores LPS-elicited rat microcirculation disorder by regulation of a network of signaling involving inhibition of TLR-4 and SRC.
Journal: American journal of physiology. Gastrointestinal and liver physiology
Published: April 21, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026